Beijing Zhongyin Technology

The company's business model is built around a comprehensive drug development system that includes target screening, basic research, animal and stem cell validation, AAV (adeno-associated virus) vector R&D, and clinical trial operations. Chigenovo employs a dual-technology platform approach, utilizing both gene replacement and gene editing therapies to address different genetic mutation mechanisms. Its clinical gene diagnosis platform has created a substantial database of genetic eye diseases in China, which informs the selection of therapeutic targets for drug development. Revenue is generated through providing precise genetic testing services and developing gene therapy drugs.

Chigenovo has several drug pipelines in development. Its leading drug candidate, ZVS101e, is a gene replacement therapy for Bietti's Crystalline Dystrophy (BCD) caused by CYP4V2 gene mutations. This drug has received Orphan Drug Designation (ODD) from the U.S. FDA and has advanced to late-stage clinical trials. Another key product, ZVS203e, is an in-vivo gene editing therapy that has also been granted ODD by the FDA. The company has secured multiple rounds of funding from investors including Kunlun Capital, Jinpu Investment, and Longpan Investment, which has accelerated the clinical and industrialization progress of its drug pipelines.